| Targeting an RNA-binding protein network in acute myeloid leukemia E Wang, SX Lu, A Pastore, X Chen, J Imig, SCW Lee, K Hockemeyer, ... Cancer Cell 35 (3), 369-384. e7, 2019 | 257 | 2019 |
| Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration O Alpdogan, VM Hubbard, OM Smith, N Patel, S Lu, GL Goldberg, ... Blood 107 (6), 2453-2460, 2006 | 252 | 2006 |
| Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation JL Zakrzewski, AA Kochman, SX Lu, TH Terwey, TD Kim, VM Hubbard, ... Nature medicine 12 (9), 1039-1047, 2006 | 224 | 2006 |
| Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations SCW Lee, K North, E Kim, E Jang, E Obeng, SX Lu, B Liu, D Inoue, ... Cancer cell 34 (2), 225-241. e8, 2018 | 213 | 2018 |
| Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity T Ramirez-Montagut, A Chow, D Hirschhorn-Cymerman, TH Terwey, ... The Journal of Immunology 176 (11), 6434-6442, 2006 | 190 | 2006 |
| Spliceosomal disruption of the non-canonical BAF complex in cancer D Inoue, GL Chew, B Liu, BC Michel, J Pangallo, AR D’Avino, T Hitchman, ... Nature 574 (7778), 432-436, 2019 | 187 | 2019 |
| Pharmacologic modulation of RNA splicing enhances anti-tumor immunity SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ... Cell 184 (15), 4032-4047. e31, 2021 | 162 | 2021 |
| Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms BH Durham, EL Rodrigo, J Picarsic, D Abramson, V Rotemberg, ... Nature medicine 25 (12), 1839-1842, 2019 | 147 | 2019 |
| Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors JL Zakrzewski, D Suh, JC Markley, OM Smith, C King, GL Goldberg, ... Nature biotechnology 26 (4), 453-461, 2008 | 140 | 2008 |
| Relapse after allogeneic hematopoietic cell therapy MRM van den Brink, DL Porter, S Giralt, SX Lu, RR Jenq, A Hanash, ... Biology of Blood and Marrow Transplantation 16 (1), S138-S145, 2010 | 135 | 2010 |
| Absence of β7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine E Waldman, SX Lu, VM Hubbard, AA Kochman, JM Eng, TH Terwey, ... Blood 107 (4), 1703-1711, 2006 | 135 | 2006 |
| Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 134 | 2022 |
| CCR2 is required for CD8-induced graft-versus-host disease TH Terwey, TD Kim, AA Kochman, VM Hubbard, S Lu, JL Zakrzewski, ... Blood 106 (9), 3322-3330, 2005 | 125 | 2005 |
| NOD2 regulates hematopoietic cell function during graft-versus-host disease O Penack, OM Smith, A Cunningham-Bussel, X Liu, U Rao, N Yim, IK Na, ... Journal of Experimental Medicine 206 (10), 2101-2110, 2009 | 114 | 2009 |
| Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations BH Durham, B Getta, S Dietrich, J Taylor, H Won, JM Bogenberger, ... Blood, The Journal of the American Society of Hematology 130 (14), 1644-1648, 2017 | 111 | 2017 |
| The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease IK Na, SX Lu, NL Yim, GL Goldberg, J Tsai, U Rao, OM Smith, CG King, ... The Journal of clinical investigation 120 (1), 343-356, 2010 | 92 | 2010 |
| COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersCOVID-19 in Patients with Multiple Myeloma M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 83 | 2020 |
| Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML A Yoshimi, ME Balasis, A Vedder, K Feldman, Y Ma, H Zhang, SCW Lee, ... Blood, The Journal of the American Society of Hematology 130 (4), 397-407, 2017 | 82 | 2017 |
| Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the … O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, ... JAMA oncology 7 (6), 862-868, 2021 | 79 | 2021 |
| Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition D Inoue, JT Polaski, J Taylor, P Castel, S Chen, S Kobayashi, SJ Hogg, ... Nature Genetics 53 (5), 707-718, 2021 | 79 | 2021 |
Malin HultcrantzMD PhD, Memorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
